Skip to content

Allogene Therapeutics ALLO Business Segments — Other operating expenses

Similar metrics at other companies

SLM logo
SLMReportable Segment — Other operating expenses
$12.48M+6.7%
F&G Annuities & Life logo
FGReportable Segment — Other operating expenses
$33M-19.5%
Hyliion logo
HYLNReportable Segment — Other operating expense
$300K0.0%
Marqeta logo
MQReportable Segment — Other operating expenses
$3.57M-9.6%
i3 Verticals, Inc. logo
IIIVReportable Segment — Other operating expenses
$5.8M+53.1%
Evolv Technologies Holdings, Inc. logo
EVLVReportable Segment — Other operating expenses
$6.88M+38.8%

Other financials

Income statement

See full
Revenue-
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherCostAndExpenseOperating.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's business segments — other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's business segments — other operating expenses?
Allogene Therapeutics (ALLO) reported business segments — other operating expenses of $11.19M in Q1 2026.
How has Allogene Therapeutics's business segments — other operating expenses changed year-over-year?
Allogene Therapeutics's business segments — other operating expenses decreased by 29.2% year-over-year, from $15.81M to $11.19M.
What is the long-term trend for Allogene Therapeutics's business segments — other operating expenses?
Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — other operating expenses has grown at a -25.0% compound annual growth rate (CAGR), from $95.37M to $53.59M.
What does business segments — other operating expenses mean?
This metric aggregates miscellaneous operating costs not captured in specific functional categories like payroll or R&D. It includes general administrative overhead and other incidental expenses necessary for day-to-day business continuity. Monitoring this helps identify potential inefficiencies or unexpected administrative burdens.